Table F-8. Key Question 2 studies with a fourth outcome

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | **Outcome #, Exact measure used** | **Timing of measurement,**  **Data Source** | **N analyzed for this outcome** | **Results by group** | **Differences in Groups** | **Covariates controlled for in analysis, Statistical methods used,** |
| Feldstein et al., 200613 | G1: Usual care (not abstracted)  G2: EMR reminder (increase reach for clinicians)  G3: EMR reminder and patient reminder (via letter with educational materials (multicomponent) | Behavioral intentions to use or apply the evidence  Physical activity (affirmative response to the query, “At least once a week, do you engage in any regular activity long enough to break a sweat?”) | Baseline and 6 months after the intervention  Patient self-report | G1: 33;  G2: 41;  G3: 42 | Post intervention=Percent G1: Pre 21.2; Post 30.3 G2: Pre 22; Post 19.5  G3: Pre 26.2; Post 28.6 | Difference:  G1 vs. G2: -10.8;\* G1 vs. G3: 1.7; \* G2 vs. G3: -9.1\* 95% CI: NR p=0.55 treatment and UC | Presurvey response  Regression analysis between treatment and usual care groups with the change of the postsurvey response from presurvey as the DV adjusting for presurvey response |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | **Outcome #, Exact measure used** | **Timing of measurement,**  **Data Source** | **N analyzed for this outcome** | **Results by group** | | **Differences in Groups** | | **Covariates controlled for in analysis, Statistical methods used,** | |
| Kennedy et al., 200319 | G1: Control (not abstracted)  G2: Information (increase reach)  G3: Interview (increase motivation) | Health-related decisions or behavior (applicable for general public/patients)  Treatment undergone. For short-term, the treatment undergone is any treatment undergone up to 12 months. For long-term followup, the data presented are cumulative and refer to any treatment undergone during the period of the study. | The 6 and 12 month data were merged together to form a “short-term” followup dataset.   24 months is labeled “long-term”  Self-report | Short-term Overall=631 G2: 205 G3: 221  Long-term Overall=729 G2: 232 G3: 253 | Short-term G2: 170 (82.9%) G3: 186 (84.2%)  Long-term G2: 204 (87.9%) G3: 212 (83.8%) | G2 vs. G3: 1.3%\*, p=NR  Long term  G2 vs. G3: 4.1%\*, p=NR | | Consultant sex; Consultant year of qualification; Age; Baseline menorrhagia severity; Baseline knowledge; Previous treatment – D&C; Previous treatment – OCP; Previous treatment – hormonal drugs; Previous treatment – non-hormonal drugs; Duration of problem; Any previous surgery; Baseline preferences; Recruitment period; Length of followup  Logistic regression | |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | **Outcome #, Exact measure used** | **Timing of measurement,**  **Data Source** | **N analyzed for this outcome** | **Results by group** | | **Differences in Groups** | | **Covariates controlled for in analysis, Statistical methods used,** | |
| Marcus et al., 200925 | G1: Contact control treatment delayed group (not abstracted)  G2: Telephone-based individualized feedback (increase motivation)  G3: Print-based individualized feedback (increase reach) | Health-related decisions or behavior (applicable for general public/patients)  Physical activity minutes per week via self-report on PAR (interviewer administered 7-day Physical Activity Recall) interview | Baseline, 6 months and 12 months  Self-report | Overall N=218 at 6 months; 205 at 12 months G1: 72 at 6 months, 69 at 12 months G2: 75 at 6 months, 70 at 12 months  G3: 71 at 6 months, 66 at 12 months | G1: 6 months: 77.67 (SD=101.79);  12 months: 81.92 (SD=127.07) G2: 6 Months: 123.32 (SD=97.64)  12 Months: 100.59 (SD=119.68)  G3: 6 Months: 129.49 (SD=156.46)  12 Months: 162.37 (SD=165.17) | Difference:  6 months: 6.17  12 months: 61.78  95% CI: NR P:  6 months: t = 0, p=0.8595  12 months: (t=2.72, p=0.0071) | | Yes  Analysis of covariance, adjusted for treatment effects for gender and seasonal differences. When overall test of between-groups differences was significant at the >05 level, the source of these differences was examined further using single-degree-of-freedom contrasts that compared the active treatment arms with each other as well as with the treatment delayed group. | |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | **Outcome #, Exact measure used** | **Timing of measurement,**  **Data Source** | **N analyzed for this outcome** | **Results by group** | | | **Differences in Groups** | | **Covariates controlled for in analysis, Statistical methods used,** | |
| Murtaugh et al., 200527 | G1: Usual care (not abstracted)  G2: Basic intervention email reminder (increase reach)  G3: Augmented intervention of email reminder + package of supporting materials (multicomponent) | Behavior (applicable for clinicians)  % performing comprehensive CHF assessment | Chart-review of subsequent RN visit, within 45 days of initial intake  Chart | 354 | | Overall N=354 G1: 3.7% G2: 13.8% G3: 23.9% | | Difference G2-G1: 10.1%, p=0.006  Difference G3-G1: 20.2%, P<0.001 Difference G3-G2: 10.1%\*, CI and p=NR | | Sociodemo-graphic variables of the RN (age, gender, race/ethnicity), Rn employment status, educational level and caseload; average baseline characteristics of patients cared for by each RN including health, functional status; geographic area where nurse provided care  Predictive multivariate modeling | |
| Partin et al., 200429 | G1: Usual care (not abstracted)  G2: Pamphlet (increase reach)  G3: Video (increase reach) | Health-related decisions or behavior (applicable for general public/patients)  PSA testing | 2 weeks and 1 year posttarget appointment  VA outpatient records | N=893 G2: 295 G3: 308 | Adjusted PSA rate w/in 2 weeks G2: 0.28  G3:0.29  Adjusted PSA w/in 1 year G2: 0.67 G3: 0.70 | | PSA w/in 2 weeks G2 vs. G3: -0.01\*, p=NR  PSA w/in 1 year G2 vs. G3: 0.70\*, p=NR | | None  Logistic regression | |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | **Outcome #, Exact measure used** | | **Timing of measurement,**  **Data Source** | | **N analyzed for this outcome** | | **Results by group** | | **Differences in Groups** | | **Covariates controlled for in analysis, Statistical methods used,** | |
| Rebbeck et al., 200631 | G1: Dissemination of guidelines by mail (increase reach)  G2: Implementation group (multicomponent) | Behavior (applicable for clinicians)  Physiotherapist clinical practice - measured as the percentage of participating physiotherapists prescribing guideline recommendations | Before, during, and after the study  self-report | | Before G1: 13 G2: 14 After G1: 12 G2: 14 During G1: 12 G2: 14 | | % Reassure patient Before G1: 41% G2: 14% After G1: 18% G2: 57% During G1: 14% G2: 46% Advise to act as usual Before G1: 8 G2: 7 After G1: 18 G2: 67 During G1: 0 G2: 31 Prescribe function Before G1: 8 G2: 7 After G1: 0 G2: 25 During G1: 0 G2: 23 | | Reassure patient Difference (between G1 and G2 after trial): 39%\* p=0.05 Advise to act as usual Difference (between G1 and G2 after trial): 49%\* p=0.04 Prescribe function Difference (between G1 and G2 after trial): 25%\* p=0.22 Prescribe exercise Difference (btn G1 and G2 after trial): 0%\* p=1.00 Prescribe medication Difference (btn G1 and G2 after trial): 1%\* p=0.10 | | NR  Chi-square test | |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | **Outcome #, Exact measure used** | | **Timing of measurement,**  **Data Source** | | **N analyzed for this outcome** | | **Results by group** | | **Differences in Groups** | | **Covariates controlled for in analysis, Statistical methods used,** | |
| Rebbeck et al., 200631 (continued) |  |  |  | |  | | Prescribe exercise Before G1: 92 G2: 100 After G1: 100 G2: 100 During G1: 100 G2: 83 Prescribe medication Before G1: 17 G2: 7 After G1: 9 G2: 8 During G1: 0 G2: 23 | |  | |  | |
| Wolters et al., 200539 | G1: Control mailed guidelines (increase reach)  G2: Intervention involving package for learning, supporting materials, decision tree, and information leaflets for patients (multicomponent) | Discussions about the evidence  Lifestyle advice given | Up to 1 years post baseline  Self-report | | N=187 G1: 92 G2: 95 | | Lifestyle advice G1: 52, 56.5% G2: 58, 61.1% | | Lifestyle advice G1 vs. G2: 4.6%\* OR: 1.32 (0.48/3.63) | | Age, group allocation, IPSS and BS  Logistic regression analysis | |

\* calculated by reviewer   
**Abbreviations:** BS=Bother score; btn=between; CHF = congestive heart failure; CI = confidence interval; D&C = dilation and curettage; DV = dependent variable; EMR = electronic medical record; G = group; IPSS=International Prostate Symptom Score; N=number; NR = not reported; OCP = oral contraceptive pill; PAR = Stanford 7-Day Physical Activity Recall; PSA = prostate-specific antigen; RN=registered nurse; SD = standard deviation; vs. = versus; w/in=within.